Braveheart Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025
Net Income	-80.23	-66.05
Asset Writedown & Restructuring Costs	62.15	62.24
Stock-Based Compensation	1.93	0.18
Change in Accounts Payable	7.77	0.9
Change in Other Net Operating Assets	1.18	0.72
Operating Cash Flow	-7.2	-2.01
Operating Cash Flow Growth	-	-
Sale (Purchase) of Intangibles	-36.57	-33.57
Investing Cash Flow	-36.61	-33.57
Issuance of Common Stock	0.1	0.1
Financing Cash Flow	124.38	124.74
Net Cash Flow	80.58	89.16
Change in Working Capital	8.95	1.62

SEC Filings: 10-K · 10-Q